TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Number of participants with Liver cancer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Number of participants with Death
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants with Liver transplantation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change from baseline in quality of sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Patient Reported Balance
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Patient Reported Pain
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Brain functional activation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Brain structure imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: clinical laboratory results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Likert Scale Measurement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Catheter infection
Endpoint domain: Adverse events/effects
Primary endpoint: Safety of intramuscular vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of intramuscular vaccination
Endpoint domain: Resource use
Primary endpoint: Change in Frequency of Urination After 6-week Intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Frequency of Urination From 6 Weeks to 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Change in Frequency of Urination From Baseline to 12 Weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: grade 3-4 adverse effects
Endpoint domain: Adverse events/effects
Primary endpoint: Maximal value of the Sepsis-related Organ Failure Assessment (SOFA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain at the end of stump
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Swelling of the skin around the ITAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Condition of the skin surrounding the ITAP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Quantification of HIV DNA and RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: p24 quantification
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of translation-competent reservoirs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treg number
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: dose limiting toxicities and adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of hypotension after anesthesia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Occurrence of an unfavorable outcome
Endpoint domain: Adverse events/effects
Primary endpoint: Change from baseline antithyroid antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Alignment Accuracy of the Knee Femoral Components in Coronal Plain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alignment Accuracy of the Knee Femoral Components in Sagittal Plain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alignment Accuracy of the Knee Tibial Components in Coronal Plain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Alignment Accuracy of the Knee Tibial Components in Sagittal Plain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Harris Hip Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical performance of diagnostic tests for SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving an SLE Responder Index Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of volunteers with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Laboratory evaluations of blood and urine samples
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Vital signs evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Electrocardiogram evaluations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Ankle-Brachial Index Difference
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Doppler Ankle-Brachial Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mean Watch BP Office Ankle-Brachial Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of Erythema and Edema
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: 6-minute hall walk distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Estimation of blood loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With a Confirmed Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: RIFLE stadium L or E
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Global response rate prior to ASCT
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LPL Protein Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients Who Had Grade 3 or Above Toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Decreased incidence of muscle cramps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Continuous Smoking Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Subjects With at Least 50% Pain Relief
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (Device)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of Treatment-Emergent Adverse Events (Anesthesia)
Endpoint domain: Adverse events/effects
Primary endpoint: Therapy-related toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Primary fascial closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Pharmacokinetic evaluations (Cmin, Cmax, AUC24, Css,av)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of seizures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Plasma Concentration of JNJ-64417184
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Knee Documentation Committee (IKDC) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Kujala Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Western Ontario Meniscal Evaluation Tool (WOMET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the plasma concentration-time curve (AUC 0-t)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from 0 to infinity (AUC [0-inf])
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of subjects with cure or improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: grade 3 RT toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants developing TIA/stroke and/or subclinical ischemic lesions
Endpoint domain: Mortality/survival
Primary endpoint: Number of participants developing neurocognitive decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Neurological Disorders Depression Inventory for Epilepsy (NDDI-E)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percentage of symptom-free days
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Treatment Failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Post operative mortality
Endpoint domain: Mortality/survival
Primary endpoint: Major adverse cardiovascular event (MACE) post operative
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Redo surgery after type 1A endoleak surgery
Endpoint domain: Adverse events/effects
Primary endpoint: Adequate relief of global IBS symptoms
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Maximal isometric knee extension power
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity of gallium Ga 68-labeled PSMA-11 PET for tumor detection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: number of patients with tumors resected with negative margins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in Advanced Glycation Endproducts (AGE) Levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in thyroid size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Pharmacodynamic effect
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily blood glucose standard deviation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Success of the Round XTENDOBUTTON™ Fixation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Primary and Assisted Patency
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Percentage of Participants With Hyperplasia at Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Hyperplasia at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) of Lumbar Spine at Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent Change From Baseline in Bone Mineral Density (BMD) of Lumbar Spine at Month 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bone Mineral Density (BMD) of Total Hip at Screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Soluble serum Syndecan-1 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epicardial adipose tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Mental health status
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Objective Tumor Response Rate - AXL Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cardiopulmonary exercise capacity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Cases Free From Trident II Acetabular Shell Revision
Endpoint domain: Mortality/survival
Primary endpoint: Change of force ratio of ground reaction forces
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of the velocity of the center of pressure (COP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of Ballooning
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major congenital malformations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Absolute blood volume measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Composite changes of weight, waist circumference and BMI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Dropout ratio during weight-loss period and maintenance period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in C-peptide
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Surveillance adherence
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Number of participants with TEAEs, SAEs and AEs leading to premature discontinuation
Endpoint domain: Adverse events/effects
Primary endpoint: Dose-normalized Cyclosporine AUC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fasting glucose and lipid profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Treatment-emergent Adverse Events (AEs) and Serious AEs (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Brain Inflammation Metrics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Absence of Major Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Change in the physical component of Quality of Life
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Participants With Plasma 25(OH)D Concentration >30ng/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Total 48-hour vasopressor exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite of in-hospital mortality
Endpoint domain: Mortality/survival
Primary endpoint: adherence to exercise intervention
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Central obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proximal Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proximal Flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of bone height change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Radiological outcome
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in IBS quality of life (QoL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Percent reduction in CTCAE grade 2/3 eosinophil-related cutaneous adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Preoperative sexual function
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Interest in sexual activity
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Area Under the Curve (AUC) of the Numeric Rating Scale at Rest (NRS-R) Pain Intensity Scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDAI 70 Response Rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Permanent Pulmonary Vein Isolation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Epinephrine Cmax in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine Tmax in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine AUC in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epinephrine T half in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pain and discomfort measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of C16G2 Gel and/or Rinse administrations
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Systolic Blood Pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positivity of CXCL13-intrathecal marker
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Renal vascular and biophysical damage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: reactive hyperemia induced peripheral arterial tone (RH-RAT) index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: butyrate, acetate and propionate concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Insulin Resistance (HOMA Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: sexual life
Endpoint domain: Life impact
Endpoint subdomain: Sexual functioning
Primary endpoint: Acute phase complication rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in SUDS following treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: levels of certain plasma proteomics
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change from Baseline in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Disease-specific survival rate
Endpoint domain: Mortality/survival
Primary endpoint: Number of Participants That Filled a Prescription in 20 Days
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Safety of Gedatolisb + PTK7-ADC
Endpoint domain: Adverse events/effects
Primary endpoint: course of severity of infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: duration until recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: overall assessment of efficacy by the physician
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of infertility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Detection of Sentinel Nodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Progression of peri-implant marginal bone loss (in mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the modified Gingival Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in the peri-implant clinical pocket depth (in mm)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: First esophageal variceal bleeding
Endpoint domain: Mortality/survival
Primary endpoint: Maximum Tolerated Dose (MTD) of Lenalidomide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Grade 3 Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Patients With Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Time to Treatment Failure
Endpoint domain: Adverse events/effects
Primary endpoint: Correlation rate of ANI scores and VAS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Completion of a minimum of at least 1 CAM assessment per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean change in Irritability Subscale scores
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change of FLACC pain scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative bioavailability of fluticasone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Symptoms of complicated grief
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of Incompletely Resected Adenomatous Polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Maximal Oxygen Capacity (VO2peak)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Total Unified Parkinson's Disease Rating Scale (UPDRS) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Patients Who Achieved PCDAI Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety of JNJ-26854165
Endpoint domain: Adverse events/effects
Primary endpoint: Time to first TC infection
Endpoint domain: Adverse events/effects
Primary endpoint: intraocular VEGF levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Interlimb Coordination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in blood concentration of syndecan-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Sensitivity of pulmonary ultrasound
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Length of time the drain remains insitu
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Number of participants failing treatment requiring NIV or invasive mechanical ventilation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Toxicity type and grade
Endpoint domain: Adverse events/effects
Primary endpoint: Appropriateness of CT imaging
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Missed pulmonary embolism
Endpoint domain: Adverse events/effects
Primary endpoint: Difference in morphine consumption
Endpoint domain: Resource use
Endpoint subdomain: Other resource use